The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers

Pharmacogenetics and Genomics
Sung Kweon ChoJae Yong Chung

Abstract

We investigated whether the UGT1A3 polymorphisms play an important role in interindividual variations in atorvastatin lactonization and lipid-lowering effect. Twenty-three healthy volunteers were administered atorvastatin 20 mg once daily for 14 days. Serum levels of lipids were measured before and 7, 13, 14, 15, 21, and 28 days after the initial dosing. Blood samples for pharmacokinetic analysis were collected up to 48 h after the last dose. The UGT1A3*2 and UGT1A1*28 polymorphism had a perfect linkage in the participants. Lactone formation was significantly higher in the UGT1A3*2 carriers. The areas under the curve of atorvastatin lactone and 2-hydroxyatorvastatin lactone were 72 and 160% higher in individuals with UGT1A3*2/*2 than UGT1A3*1/*1, respectively. The maximum percent decreases in the total and the low-density lipoprotein cholesterol from baseline in UGT1A3*2 carriers were 29 and 18% less than the UGT1A3*2 noncarriers, respectively. The UGT1A3*2 polymorphism is correlated with increased atorvastatin lactonization and may affect its lipid-lowering effect.

References

Apr 16, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Thomayant PrueksaritanontThomas A Baillie
Dec 5, 2002·Pharmacogenetics·Federico InnocentiAnna Di Rienzo
Jun 18, 2003·Clinical Pharmacology and Therapeutics·Yohei NishizatoYuichi Sugiyama
May 3, 2005·Pharmacogenetics and Genomics·Federico InnocentiMark J Ratain
Oct 4, 2005·Clinical Pharmacology and Therapeutics·Jae-Yong ChungIn-Jin Jang
Apr 26, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ji-Youn HanJin Soo Lee
May 9, 2006·Clinical Pharmacology and Therapeutics·Michael IgelKari T Kivistö
May 2, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Theunis C GoosenCho-Ming Loi
Sep 28, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Donglu ZhangW Griffith Humphreys
Feb 26, 2008·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Ine Blankenberg SkottheimAnders Asberg
Oct 28, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y AkiyamaY Sasaki
Jan 16, 2009·The New England Journal of Medicine·Juan Miguel BerguaHelena Bañas
Jan 16, 2009·The New England Journal of Medicine·Georgirene D Vladutiu, Paul J Isackson
May 29, 2009·Clinical Pharmacology and Therapeutics·J E KeskitaloM Niemi
Oct 2, 2009·Clinical Pharmacology and Therapeutics·S RiedmaierU M Zanger
Nov 27, 2009·Circulation Research·Michael J KnauerRommel G Tirona
Jun 29, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Yong LiuMark J Ratain
May 5, 2011·Frontiers in Neuroscience·Y-F TanJ M Wojtowicz
May 12, 2011·Drug Metabolism and Drug Interactions·Jaroslav A Hubacek, Michal Vrablik
Jun 22, 2011·Pharmacogenetics and Genomics·Ichiro IeiriYuichi Sugiyama
Aug 20, 2011·Frontiers in Pharmacology·Stephan RiedmaierUlrich M Zanger

❮ Previous
Next ❯

Citations

Apr 13, 2013·Molecular Diagnosis & Therapy·Camilla StormoMarianne K Kringen
Jan 26, 2016·Pharmacology & Therapeutics·Zofia MazerskaEwa Augustin
Dec 17, 2015·Pharmacogenomics·Maarten LeusinkAnke H Maitland-van der Zee
Apr 5, 2016·Pharmacogenomics·Jessica CusatoAntonio D'Avolio
Aug 5, 2017·PloS One·Kleanthi LakiotakiGeorge Potamias
Dec 22, 2019·Journal of Clinical Medicine·Richard Myles Turner, Munir Pirmohamed
Nov 24, 2016·The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG·Jonathan Wagner, Susan M Abdel-Rahman
Mar 5, 2020·Clinical Pharmacology and Therapeutics·Richard M TurnerMunir Pirmohamed
Dec 5, 2018·Cancer Chemotherapy and Pharmacology·W Venus SoJianguo Zhi
Dec 31, 2020·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Dasean T Nardone-WhiteKlarissa D Jackson
Nov 17, 2020·Frontiers in Genetics·Ping Siu KeeSimran D S Maggo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.